Sunesis Pharmaceuticals Inc. | Key People and Executives
Dayton Misfeldt
Chief Executive Officer & Director
James W. Young
Non-Executive Chairman
Steven B. Ketchum
Independent Director
Henry Ward Wolff
Independent Director
Homer L. Pearce
Independent Director
David C. Stump
Independent Director
Steve Carchedi
Independent Director
Dayton Misfeldt
Chief Executive Officer & Director
Deepali Suri
Vice President-Clinical Operations
Willie P. Quinn
CFO, Senior VP-Finance & Corporate Development
Judith A. Fox
Chief Scientific Officer
Stephen Nava
Vice President-Compliance & Regulatory Affairs
Sean Gharpurey
Executive Director-Project Management
Gene C. Jamieson
Vice President-Technical Operations
Jennifer A. Smith
Vice President-Biometrics
Parvinder S. Hyare
Vice President-Global Oncology Operations
Deborah A. Thomas
Senior VP-Regulatory Affairs, Quality Assurance
James W. Young
Non-Executive Chairman
Steven B. Ketchum
Independent Director
Henry Ward Wolff
Independent Director
Homer L. Pearce
Independent Director
David C. Stump
Independent Director
Steve Carchedi
Independent Director
| Address |
395 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.sunesis.com |
| Updated |
07/08/2019 |
| Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. |
